The leader in quality education and networking through//conferences, courses and custom training
Connect with IBC Life Sciences:LinkedIn iconTwitter iconFacebook iconRSS icon

AsiaTIDES: Oligonucleotide and Peptide Research, Technology and Product Development


Where Global Oligonucleotide and Peptide Leaders Connect to Share Groundbreaking Science and Form Successful Business Collaborations

February 25 - February 27,--> 2014 · Tokyo, Japan

Event Overview

Event Overview

Accelerate Your Oligonucleotide and Peptide Discovery and Development Programs

  • Benchmark Your Current Portfolio with 20 Global Case Studies and New Data Presentations Covering the Latest Preclinical and Clinical Updates
  • Navigate the IND /NDA Landscape For Your Viable Drug with Regulatory and Safety Considerations from Two Former FDA Officials
  • Develop Patient-Friendly Routes of Administration for your Oligonucleotide and Peptide Therapeutics by Hearing Comprehensive Updates on Current Proposed Drug Delivery Systems
  • Reach New, Untapped Markets by Forging Global Partnerships with Key Market Leaders in Asia, Europe and North America
  • Stay Ahead of the Competition by Accessing the Latest Oligonucleotide and Peptide Technologies, Services and Cutting-Edge Research in our Expanded Exhibit and Poster Hall

AsiaTIDES 2013 Presentations Now Available!
» Learn More

"AsiaTIDES is the preeminent conference in Japan on the development of therapeutic oligos and peptides, and brings together a majority of the leaders in the field." - Patrick C. Reid, Ph.D., Chief Scientific Officer, PeptiDream Inc., Japan

"AsiaTIDES is a well-organized, informative meeting providing a great overview of the oligonucleotide field and the opportunity to network with current and potential collaborators in a nice setting." - Pamela A. Pavco, Ph.D., Chief Development Officer, RXi Pharmaceuticals, USA

Advance Your Oligonucleotide and Peptide Therapeutics Towards Commercial Success

IBC Life Sciences' 6th Annual AsiaTIDES conference continues to provide the evolving oligonucleotide and peptide therapeutic fields in Japan and throughout Asia with a forum to share the latest groundbreaking science and form successful business collaborations.

Access up-to-date development reports from Aileron Therapeutics Inc., AM Biotechnologies, Bicycle Therapeutics, BIONEER, Immunovaccine Inc., InDex, Isis, miRagen, Nexigen GmbH, Noxxon, OncoTherapy, RXi Pharmaceuticals, Santaris Pharma, and more.

Hear regulatory and safety assessment considerations for peptides and oligonucleotides from two former U.S. Food and Drug Administration Officials, and a case study on whether the ICH-S6(R1) guideline is applicable for oligonucleotides.

Learn manufacturing capabilities from major oligonucleotide and peptide CMOs and understand what is happening on the academic research front.

Plus! Gain immediately applicable knowledge from three tutorials for 2014: Manufacturing of Oligonucleotide Drugs, The Challenge of Oligonucleotide In Vivo Delivery; and Evolution of a CMC Section Throughout a Peptide Product Life Cycle.

Access the latest updates on science, business developments, and regulatory challenges in just three days. Don't miss this opportunity to network with leaders around the world and reinforce your development portfolio.

"The best RNAi Therapeutics-related conference in Asia! A great place to network, connect the East and West, and catch up with the latest cutting-edge science." - Dirk Haussecker, D. Phil, Assistant Professor, Medical Biotechnology, Dongguk University, South Korea

TIDES 2014